Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.53 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.53 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11599423 | 0.98 | MAPT (0.64) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL8087422 | 0.98 | MAPT (0.64) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL7247766 | 0.93 | HDAC1 (0.61) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL1603029 | 0.83 | KEAP1 (0.58) | MAPTHDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL7773710 | 0.83 | MAPT (0.57) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL6896603 | 0.83 | MAPT (0.57) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL2726125 | 0.83 | MAPT (0.57) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL9052095 | 0.81 | MAPT (0.60) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL7771090 | 0.81 | MAPT (0.60) | MAPTRXFP1HDAC1HDAC2HDAC3 | |
| SCHEMBL7771094 | 0.81 | MAPT (0.60) | MAPTRXFP1HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008007391-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF VALSARTAN | SATYANARAYANA REDDY MANNE (IN) | 2008-01-17 | — | — | WO | claimed |
| US-8492577-B2 | Process for preparation of valsartan intermediate | HETERO RESEARCH FOUNDATION (IN) | 2013-07-23 | — | — | US | disclosed |
| US-20110237822-A1 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2011-09-29 | — | — | US | disclosed |
| EP-2260018-A2 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | Hetero Research Foundation (IN) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009125416-A2 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2009-10-15 | — | — | WO | disclosed |
| EP-1313751-B1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2008007391-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF VALSARTAN | SATYANARAYANA REDDY MANNE (IN) | 2008-01-17 | — | — | WO | disclosed |
| US-5998433-A | THERAPY FOR HYPERLIPIDEMIA; ATHEROSCLEROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| CN-1160403-A | Substd. heterobicyclic alkyl amines and their use as squalene oxide cyclase inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-09-24 | — | — | CN | disclosed |
| EP-0785939-A1 | SUBSTITUTED HETEROBICYCLIC ALKYL AMINES AND THEIR USE AS SQUALENE OXIDE CYCLASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 1997-07-30 | — | — | EP | disclosed |
| US-5633379-A | N-METHYLASPARTIC ACID ANTAGONIST | CIBA-GEIGY CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
| WO-1996011201-A1 | SUBSTITUTED HETEROBICYCLIC ALKYL AMINES AND THEIR USE AS SQUALENE OXIDE CYCLASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237822-A1 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | REN, AGT, ACE | MAPT 1677/4885RXFP1 3587/4885HDAC1 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.